Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Palmitoyl-Carnitine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | GMNN | O75496 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.97 |
| ▸ | TP53 | P04637 | 3/20 | 0.97 |
| ▸ | TSHR | P16473 | 3/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.97 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.74 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17667555 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNAGMNNNPSR1 | |
| Hydrochloric Acid SCHEMBL8620445 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNAGMNNNPSR1 | |
| Hydrochloric Acid SCHEMBL8580303 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNAGMNNNPSR1 | |
| Hydrochloric Acid SCHEMBL1321243 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNAGMNNNPSR1 | |
| Hydrochloric Acid SCHEMBL8580295 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNAGMNNNPSR1 | |
| Octanoylcarnitine SCHEMBL16535179 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNAGMNNNPSR1 | |
| Palmitoyl-Carnitine SCHEMBL2785480 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNAGMNNNPSR1 | |
| Hydrochloric Acid SCHEMBL8620442 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNAGMNNNPSR1 | |
| Hydrochloric Acid SCHEMBL8620437 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNAGMNNNPSR1 | |
| Palmitoyl-Carnitine SCHEMBL20580076 | 1.00 | MAPK1 (1.00) | MAPK1MAPTLMNAGMNNNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007619-A1 | Sublingual Epinephrine Compositions Including pH-Modifying Excipients And Penetration Enhancers And Methods for Use Thereof | NOVA SOUTHEASTERN UNIVERSITY (US) | 2026-01-08 | — | — | US | claimed |
| US-20260007622-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | UNIV FLORIDA STATE RES FOUND (US) | 2026-01-08 | — | — | US | claimed |
| EP-4651897-A1 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | Syntis Bio, Inc. (US) | 2025-11-26 | — | — | EP | claimed |
| US-12357591-B2 | Sublingual epinephrine compositions including pH-modifying excipients and penetration enhancers and methods for use thereof | NOVA SOUTHEASTERN UNIVERSITY (US) | 2025-07-15 | — | — | US | claimed |
| US-20250041253-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2025-02-06 | — | — | US | claimed |
| US-20240261411-A1 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | SYNTIS BIO, INC. | 2024-08-08 | — | — | US | claimed |
| WO-2024155958-A1 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | SYNTIS BIO, INC. (US) | 2024-07-25 | — | — | WO | claimed |
| CN-118105365-A | Use of a compound in the manufacture of a medicament for preventing or treating idiopathic vomiting in a companion animal | 马斯公司 | 2024-05-31 | — | — | CN | claimed |
| US-20230390225-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2023-12-07 | — | — | US | claimed |
| US-20220000806-A1 | Sublingual Epinephrine Compositions Including pH-Modifying Excipients And Penetration Enhancers And Methods for Use Thereof | NOVA SOUTHEASTERN UNIVERSITY (US) | 2022-01-06 | — | — | US | claimed |
| US-8609139-B2 | Formulations for enhanced bioavailability of orally administered polar agents | ALA WAI PHARMA, INC. (US) | 2013-12-17 | — | — | US | claimed |
| US-20110206764-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | UNIVERSITY OF HAWAII | 2011-08-25 | — | — | US | claimed |
| EP-2217216-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | Scolr Pharma, Inc. (US) | 2010-08-18 | — | — | EP | claimed |
| WO-2009061805-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SCOLR PHARMA, INC. (US) | 2009-05-14 | — | — | WO | claimed |
| US-20020137692-A1 | Novel compositions of potassium channel openers and protein kinase C inhibitors and use thereof | PHARMACIA AB | 2002-09-26 | — | — | US | claimed |
| EP-1225916-A1 | COMPOSITIONS AND METHODS FOR CONTROLLED-RELEASE DELIVERY AND INCREASED POTENCY OF PHARMACEUTICALS VIA HYDROPHOBIC ION-PAIRING | University Technology Corporation (US) | 2002-07-31 | — | — | EP | claimed |
| WO-2001032218-A1 | COMPOSITIONS AND METHODS FOR CONTROLLED-RELEASE DELIVERY AND INCREASED POTENCY OF PHARMACEUTICALS VIA HYDROPHOBIC ION-PAIRING | UNIVERSITY TECHNOLOGY CORPORATION (US) | 2001-05-10 | — | — | WO | claimed |
| WO-1999041984-A9 | INTERACTION BETWEEN THE MEC1-DEPENDENT DNA SYNTHESIS CHECKPOINT AND G1 CYCLIN FUNCTION IN $i(SACCAROMYCES CEREVISIAE) | HUTCHINSON FRED CANCER RES (US) | 1999-11-04 | — | — | WO | claimed |
| WO-1999041984-A1 | INTERACTION BETWEEN THE MEC1-DEPENDENT DNA SYNTHESIS CHECKPOINT AND G1 CYCLIN FUNCTION IN $i(SACCAROMYCES CEREVISIAE) | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 1999-08-26 | — | — | WO | claimed |
| US-5525596-A | (R-(R*,R*))-3-((2-HYDROXYPROPYL)AMINO)-3-METHYL-N-2,3,4,5-TET RAHYDRO-2-OXO-1-((2'-(H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)ME THYL-1H-1-BENZAZEPIN-3-YL)BUTANAMIDE, PALMITOYL CARNITINE AND CYCLODEXTRIN | MERCK & CO., INC. (US) | 1996-06-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041253-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | TMPRSS2, NCSTN, PRSS2 | MAPK1 3318/4885MAPT 1557/4885LMNA 3485/4885 |
| US-20240261411-A1 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | FABP2, SLC10A2, FABP6 | MAPK1 3260/4885MAPT 4404/4885LMNA 4353/4885 |
| US-20230390225-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | TMPRSS2, NCSTN, PRSS2 | MAPK1 3318/4885MAPT 1557/4885LMNA 3485/4885 |
| US-20260007622-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | TMPRSS2, PKD2, DSP | MAPK1 2391/4885MAPT 1835/4885LMNA 1816/4885 |
| US-20260007619-A1 | Sublingual Epinephrine Compositions Including pH-Modifying Excipients And Penetration Enhancers And Methods for Use Thereof | CMA1, ADRB3, ENPP2 | MAPK1 2807/4885MAPT 2116/4885LMNA 1000/4885 |
| US-20110206764-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | MAPK1 1997/4885MAPT 3202/4885LMNA 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.